
RealRate

PHARMACEUTICAL 2017

PROVECTUS BIOPHARMACEUTICALS INC. Rank 305 of 313



RealRate

PHARMACEUTICAL 2017

PROVECTUS BIOPHARMACEUTICALS INC. Rank 305 of 313

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 1,423% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Other Net Income, reducing the Economic Capital Ratio by 2,491% points.

The company's Economic Capital Ratio, given in the ranking table, is -2,460%, being 2,043% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	1,826
Cost of Goods Sold	0
Intangible Assets	2,241
Liabilities, Current	2,142
Liabilities, Non-Current	0
Other Assets	1,471
Other Compr. Net Income	0
Other Expenses	436
Other Liabilities	0
Other Net Income	-23,991
Property and Equipment	72
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	5,611
Liabilities	2,142
Expenses	436
Stockholders Equity	3,469
Net Income	-24,427
Comprehensive Net Income	-24,427
Economic Capital Ratio	-2,460%